Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cioranib
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cioranib (CS055) is a novel, orally bioavailable multi-target kinase inhibitor developed by Chipscreen Biosciences and its innovative drug discovery arm, Chipscreen NewWay. It is designed to simultaneously inhibit several key pathways involved in tumor progression: Aurora B kinase (involved in cell mitosis), the VEGFR and PDGFR families (involved in angiogenesis), and c-Kit/CSF1R (involved in the tumor microenvironment and immune evasion). This multi-pronged approach aims to overcome resistance mechanisms common in monotherapy. Cioranib is currently in late-stage clinical development, with Phase 3 trials ongoing for small cell lung cancer and ovarian cancer, and Phase 2 trials for other solid tumors such as triple-negative breast cancer and liver cancer.
- Other names
- 西奥罗尼Cioronil
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)AURKB (Aurora kinase B)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on cioranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cioranib.